Daratumumab Combined with Dexamethasone and Lenalidomide or Bortezomib in Relapsed/refractory Multiple Myeloma (RRMM) Patients: Report from the Multiple Myeloma GIMEMA Lazio Group

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jul 18

PMID 35846211

Authors

Francesca Fazio

Luca Franceschini

Valeria Tomarchio

Angela Rago

Maria Grazia Garzia

Luca Cupelli

Velia Bongarzoni

Alessandro Andriani

Svitlana Gumenyuk

Agostino Tafuri

Agostina Siniscalchi

Alfonso Piciocchi

Paolo de Fabritiis

Luca de Rosa

Tommaso Caravita di Toritto

Ombretta Annibali

Maria Cantonetti

Maria Teresa Petrucci

Affiliations

Soon will be listed here.

Abstract

The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression-free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment-emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real-life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.

Citing Articles

Multiple Myeloma in 2023 Ways: From Trials to Real Life.

Fazio M, Del Fabro V, Parrinello N, Allegra A, Markovic U, Botta C Curr Oncol. 2023; 30(11):9710-9733.

PMID: 37999125 PMC: 10670159. DOI: 10.3390/curroncol30110705.

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications.

Shi H, Wei W, Peng R, Chen H, Zhou N, Wu L Front Oncol. 2023; 13:1185991.

PMID: 37284198 PMC: 10240086. DOI: 10.3389/fonc.2023.1185991.

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.

Stork M, Spicka I, Radocha J, Minarik J, Jelinek T, Jungova A Ann Hematol. 2023; 102(6):1501-1511.

PMID: 37088816 PMC: 10182121. DOI: 10.1007/s00277-023-05188-4.

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.

Fazio F, Franceschini L, Tomarchio V, Rago A, Garzia M, Cupelli L EJHaem. 2022; 3(1):121-128.

PMID: 35846211 PMC: 9175681. DOI: 10.1002/jha2.359.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Palumbo A, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M . Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375(8):754-66. DOI: 10.1056/NEJMoa1606038. View

Lovas S, Varga G, Farkas P, Masszi T, Wohner N, Bereczki A . Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. Int J Hematol. 2019; 110(5):559-565. DOI: 10.1007/s12185-019-02715-w. View

Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai Y . Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013; 122(7):1243-55. PMC: 3744991. DOI: 10.1182/blood-2013-02-483511. View

Soekojo C, Ooi M, De Mel S, Chng W . Immunotherapy in Multiple Myeloma. Cells. 2020; 9(3). PMC: 7140529. DOI: 10.3390/cells9030601. View

Kobayashi H, Tsushima T, Terao T, Abe Y, Miura D, Narita K . Evaluation of the safety and efficacy of daratumumab outside of clinical trials. Int J Hematol. 2019; 109(6):665-672. DOI: 10.1007/s12185-019-02648-4. View

Nishida H, Yamada T . Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. J Oncol. 2019; 2019:6084012. PMC: 6875016. DOI: 10.1155/2019/6084012. View

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K . Human CD38: a glycoprotein in search of a function. Immunol Today. 1994; 15(3):95-7. DOI: 10.1016/0167-5699(94)90148-1. View

10.

Byun J, Yoon S, Koh Y, Kim I, Jo J, Park H . Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience. Anticancer Res. 2019; 39(9):5165-5170. DOI: 10.21873/anticanres.13712. View

11.

de Weers M, Tai Y, van der Veer M, Bakker J, Vink T, Jacobs D . Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2010; 186(3):1840-8. DOI: 10.4049/jimmunol.1003032. View

12.

Bonello F, Mina R, Boccadoro M, Gay F . Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers (Basel). 2019; 12(1). PMC: 7017131. DOI: 10.3390/cancers12010015. View

13.

Santonocito A, Consoli U, Bagnato S, Milone G, Palumbo G, Di Raimondo F . Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res. 2004; 28(5):469-77. DOI: 10.1016/j.leukres.2003.09.015. View

14.

Mateos M, Dimopoulos M, Cavo M, Suzuki K, Jakubowiak A, Knop S . Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2017; 378(6):518-528. DOI: 10.1056/NEJMoa1714678. View

15.

Jullien M, Trudel S, Tessoulin B, Mahe B, Dubruille V, Blin N . Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. Ann Hematol. 2019; 98(6):1435-1440. DOI: 10.1007/s00277-019-03655-5. View

16.

Lonial S, Weiss B, Usmani S, Singhal S, Chari A, Bahlis N . Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016; 387(10027):1551-1560. DOI: 10.1016/S0140-6736(15)01120-4. View

17.

Antonioli E, Staderini M, Pilerci S, Perfetto F, Cappelli F, Allinovi M . Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience. Leuk Lymphoma. 2020; 61(13):3255-3258. DOI: 10.1080/10428194.2020.1802452. View

18.

Fazio F, Franceschini L, Tomarchio V, Rago A, Garzia M, Cupelli L . Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. EJHaem. 2022; 3(1):121-128. PMC: 9175681. DOI: 10.1002/jha2.359. View

19.

Lokhorst H, Plesner T, Laubach J, Nahi H, Gimsing P, Hansson M . Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015; 373(13):1207-19. DOI: 10.1056/NEJMoa1506348. View

20.

Lakshman A, Abeykoon J, Kumar S, Rajkumar S, Dingli D, Buadi F . Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol. 2017; 92(11):1146-1155. DOI: 10.1002/ajh.24883. View